Efficient liver repopulation of transplanted hepatocyte prevents cirrhosis in a rat model of hereditary tyrosinemia type i

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Zhang, Ludi ^a   Shao, Yanjiao ^b   Li, Lu ^a   Tian, Feng ^c   Cen, Jin ^a   Chen, Xiaotao ^a   Hu, Dan ^d   Zhou, Yan ^d   Xie, Weifen ^e   Zheng, Yunwen ^f   Ji, Yuan ^c   Liu, Mingyao ^b   Li, Dali ^b   Hui, Lijian ^a  

^a INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

^b EAST CHINA NORMAL UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

^d EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^e SECOND MILITARY MEDICAL UNIVERSITY   (China)

^f UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FUMARYLACETOACETASE; HYDROLASE;

ANIMAL; CELL CULTURE; COMPLICATION; CRISPR CAS SYSTEM; CYTOLOGY; DISEASE MODEL; GENETICS; HUMAN; LIVER; LIVER CELL; LIVER CIRRHOSIS; PATHOLOGY; RAT; TRANSPLANTATION; TYROSINEMIA;

ANIMALS; CELLS, CULTURED; CRISPR-CAS SYSTEMS; DISEASE MODELS, ANIMAL; HEPATOCYTES; HUMANS; HYDROLASES; LIVER; LIVER CIRRHOSIS; RATS; TYROSINEMIAS;

EID: 84982190079     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep31460     Document Type: Article

References (56)

1. Lindblad, B., Lindstedt, S. & Steen, G. On the enzymic dEffects in hereditary tyrosinemia. Proceedings of the National Academy of Sciences of the United States of America 74, 4641-4645 (1977).
2. Kvittingen, E. A. Hereditary tyrosinemia type I-an overview. Scandinavian journal of clinical and laboratory investigation. Supplementum 184, 27-34 (1986).
3. Tanguay, R. M. et al. Diferent molecular basis for fumarylacetoacetate hydrolase defciency in the two clinical forms of hereditary tyrosinemia (type I). American journal of human genetics 47, 308-316 (1990).
4. St-Louis, M. & Tanguay, R. M. Mutations in the fumarylacetoacetate hydrolase gene causing hereditary tyrosinemia type I: overview. Human mutation 9, 291-299, doi: 10.1002/(SICI)1098-1004(1997)9:43.0.CO;2-9 (1997).
5. Scriver, C. R. The metabolic & molecular bases of inherited disease. Vol. 4 (New York; Montreal: McGraw-Hill, 2001).
6. Russo, P. & O'Regan, S. Visceral pathology of hereditary tyrosinemia type I. American journal of human genetics 47, 317-324 (1990).
7. Lindstedt, S., Holme, E., Lock, E. A., Hjalmarson, O. & Strandvik, B. Treatment of Hereditary Tyrosinemia Type-I by Inhibition of 4-Hydroxyphenylpyruvate Dioxygenase. Lancet 340, 813-817, doi: 10.1016/0140-6736(92)92685-9 (1992).
8. Masurel-Paulet, A. et al. NTBC treatment in tyrosinaemia type I: Long-term outcome in French patients. J Inherit Metab Dis 31, 81-87, doi: 10.1007/s10545-008-0793-1 (2008).
9. McKiernan, P. J. Nitisinone in the treatment of hereditary tyrosinaemia type 1. Drugs 66, 743-750, doi: 10.2165/00003495-200666060-00002 (2006).
10. Mohan, N. et al. Indications and outcome of liver transplantation in tyrosinaemia type 1. European journal of pediatrics 158 Suppl 2, S49-S54 (1999).
11. Grompe, M. et al. Loss of Fumarylacetoacetate Hydrolase Is Responsible for the Neonatal Hepatic-Dysfunction Phenotype of Lethal Albino Mice. Genes & Development 7, 2298-2307, doi: 10.1101/Gad.7.12a.2298 (1993).
12. Hickey, R. D. et al. Fumarylacetoacetate hydrolase defcient pigs are a novel large animal model of metabolic liver disease. Stem cell research 13, 144-153, doi: 10.1016/j.scr.2014.05.003 (2014).
13. Hickey, R. D. et al. Efcient Production of Fah-Null Heterozygote Pigs by Chimeric Adeno-Associated Virus-Mediated Gene Knockout and Somatic Cell Nuclear Transfer. Hepatology 54, 1351-1359, doi: 10.1002/hep.24490 (2011).
14. Gluecksohnwaelsch, S. Genetic-Control of Morphogenetic and Biochemical Diferentiation-Lethal Albino Deletions in the Mouse. Cell 16, 225-237, doi: 10.1016/0092-8674(79)90001-1 (1979).
15. Aponte, J. L. et al. Point mutations in the murine fumarylacetoacetate hydrolase gene: Animal models for the human genetic disorder hereditary tyrosinemia type 1. Proceedings of the National Academy of Sciences of the United States of America 98, 641-645, doi: 0.1073/Pnas.98.2.641 (2001).
16. Grompe, M. et al. Pharmacological Correction of Neonatal Lethal Hepatic-Dysfunction in a Murine Model of Hereditary Tyrosinemia Type-I. Nature genetics 10, 453-460, doi: 10.1038/Ng0895-453 (1995).
17. Overturf, K. et al. Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinaemia type I. Nature genetics 12, 266-273, doi: 10.1038/Ng0396-266 (1996).
18. Azuma, H. et al. Robust expansion of human hepatocytes in Fah-/-/Rag2-/-/Il2rg-/-mice. Nature biotechnology 25, 903-910, doi: 10.1038/nbt1326 (2007).
19. Huch, M. et al. In vitro expansion of single Lgr5 + liver stem cells induced by Wnt-driven regeneration. Nature 494, 247-250, doi: 10.1038/nature11826 (2013).
20. Tarlow, B. D. et al. Bipotential adult liver progenitors are derived from chronically injured mature hepatocytes. Cell stem cell 15, 605-618, doi: 10.1016/j.stem.2014.09.008 (2014).
21. Huang, P. et al. Direct reprogramming of human fbroblasts to functional and expandable hepatocytes. Cell stem cell 14, 370-384, doi: 10.1016/j.stem.2014.01.003 (2014).
22. Zhu, S. Y. et al. Mouse liver repopulation with hepatocytes generated from human fbroblasts. Nature 508, 93-97, doi: 10.1038/nature13020 (2014).
23. Bissig, K. D. et al. Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment. Journal of Clinical Investigation 120, 924-930, doi: 10.1172/JCI40094 (2010).
24. Lagasse, E. et al. Purifed hematopoietic stem cells can diferentiate into hepatocytes in vivo. Nature medicine 6, 1229-1234, doi: 10.1038/81326 (2000).
25. Wang, X., Al-Dhalimy, M., Lagasse, E., Finegold, M. & Grompe, M. Liver repopulation and correction of metabolic liver disease by transplanted adult mouse pancreatic cells. American Journal of Pathology 158, 571-579, doi: 10.1016/S0002-9440(10)63999-5 (2001).
26. Mashimo, T. et al. Generation and Characterization of Severe Combined Immunodefciency Rats. Cell reports 2, 685-694, doi: 10.1016/j.celrep.2012.08.009 (2012).
27. Zheng, S., Geghman, K., Shenoy, S. & Li, C. Retake the center stage-new development of rat genetics. Journal of genetics and genomics = Yi chuan xue bao 39, 261-268, doi: 10.1016/j.jgg.2012.05.003 (2012).
28. Popov, Y. & Schuppan, D. Targeting Liver Fibrosis: Strategies for Development and Validation of Antifbrotic Terapies. Hepatology 50, 1294-1306, doi: 10.1002/hep.23123 (2009).
29. Jacob, H. J. & Kwitek, A. E. Rat genetics: Attaching physiology and pharmacology to the genome. Nat Rev Genet 3, 33-42, doi: 10.1038/Nrg702 (2002).
30. Kuijk, E. W. et al. Generation and characterization of rat liver stem cell lines and their engrafment in a rat model of liver failure. Scientifc reports 6, 22154, doi: 10.1038/srep22154 (2016).
31. Li, W., Teng, F., Li, T. D. & Zhou, Q. Simultaneous generation and germline transmission of multiple gene mutations in rat using CRISPR-Cas systems. Nature biotechnology 31, 684-686, doi: 10.1038/nbt.2652 (2013).
32. Li, D. L. et al. Heritable gene targeting in the mouse and rat using a CRISPR-Cas system. Nature biotechnology 31, 681-683, doi: 10.1038/nbt.2661 (2013).
33. Shao, Y. J. et al. CRISPR/Cas-mediated genome editing in the rat via direct injection of one-cell embryos. Nature protocols 9, 2493-2512, doi: 10.1038/nprot.2014.171 (2014).
34. Hsu, P. D. et al. DNA targeting specifcity of RNA-guided Cas9 nucleases. Nature biotechnology 31, 827-+, doi: 10.1038/nbt.2647 (2013).
35. Iyer, V. et al. Of-target mutations are rare in Cas9-modifed mice. Nature methods 12, 479, doi: 10.1038/nmeth.3408 (2015).
36. Scott, C. R. The genetic tyrosinemias. American journal of medical genetics. Part C, Seminars in medical genetics 142C, 121-126, doi: 10.1002/ajmg.c.30092 (2006).
37. Willenbring, H. et al. Loss of p21 permits carcinogenesis from chronically damaged liver and kidney epithelial cells despite unchecked apoptosis. Cancer cell 14, 59-67, doi: 10.1016/j.ccr.2008.05.004 (2008).
38. Scheuer, P. J. Classifcation of chronic viral hepatitis: a need for reassessment. Journal of hepatology 13, 372-374 (1991).
39. Grompe, M. & Strom, S. Mice with human livers. Gastroenterology 145, 1209-1214, doi: 10.1053/j.gastro.2013.09.009 (2013).
40. Huang, P. Y. et al. Induction of functional hepatocyte-like cells from mouse fbroblasts by defned factors. Nature 475, 386-U142, doi: 10.1038/nature10116 (2011).
41. Overturf, K. et al. Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinaemia type I (vol 12, pg 266, 1996). Nature genetics 12, 458-458 (1996).
42. De Vree, J. M. L. et al. Correction of liver disease by hepatocyte transplantation in a mouse model of progressive familial intrahepatic cholestasis. Gastroenterology 119, 1720-1730, doi: 10.1053/Gast.2000.20222 (2000).
43. Malhi, H., Irani, A. N., Volenberg, I., Schilsky, M. L. & Gupta, S. Early cell transplantation in LEC rats modeling Wilson's disease eliminates hepatic copper with reversal of liver disease. Gastroenterology 122, 438-447, doi: 10.1053/gast.2002.31086 (2002).
44. Laconi, E., Sarma, D. S. R. & Pani, P. Transplantation of Normal Hepatocytes Modulates the Development of Chronic Liver-Lesions Induced by a Pyrrolizidine Alkaloid, Lasiocarpine. Carcinogenesis 16, 139-142, doi: 10.1093/Carcin/16.1.139 (1995).
45. Forbes, S. J., Gupta, S. & Dhawan, A. Cell therapy for liver disease: From liver transplantation to cell factory. Journal of hepatology 62, S157-S169 (2015).
46. Kobayashi, N. et al. Hepatocyte transplantation in rats with decompensated cirrhosis. Hepatology 31, 851-857, doi: 10.1053/he.2000.5636 (2000).
47. Gagandeep, S. et al. Transplanted hepatocytes engraf, survive, and proliferate in the liver of rats with carbon tetrachloride-induced cirrhosis. J Pathol 191, 78-85, doi: Doi 10.1002/(Sici)1096-9896(200005)191:178:Aid-Path5873.0.Co;2-P (2000).
48. Yovchev, M. I., Xue, Y. H., Shafritz, D. A., Locker, J. & Oertel, M. Repopulation of the Fibrotic/Cirrhotic Rat Liver by Transplanted Hepatic Stem/Progenitor Cells and Mature Hepatocytes. Hepatology 59, 284-295, doi: 10.1002/hep.26615 (2014).
49. Manuelpillai, U. et al. Transplantation of Human Amnion Epithelial Cells Reduces Hepatic Fibrosis in Immunocompetent CCl4-Treated Mice. Cell transplantation 19, 1157-1168, doi: 10.3727/096368910X504496 (2010).
50. Harn, H. J. et al. Adipose-Derived Stem Cells Can Abrogate Chemical-Induced Liver Fibrosis and Facilitate Recovery of Liver Function. Cell transplantation 21, 2753-2764, doi: 10.3727/096368912X652959 (2012).
51. Lin, S. Z. et al. Transplantation of Human Wharton's Jelly-Derived Stem Cells Alleviates Chemically Induced Liver Fibrosis in Rats. Cell transplantation 19, 1451-1463, doi: 10.3727/096368910X514198 (2010).
52. He, Z. et al. Liver xeno-repopulat ion with human hepatoc ytes in Fah-/-R ag2-/-mice afer pharmacological immunosuppression. The American journal of pathology 177, 1311-1319, doi: 10.2353/ajpath.2010.091154 (2010).
53. Huang, J. et al. RAG1/2 Knockout Pigs with Severe Combined Immunodefciency. J Immunol 193, 1496-1503, doi: 10.4049/jimmuno1.1400915 (2014).
54. Ji, S. Y., Zhang, L. D. & Hui, L. J. Cell fate conversion: Direct induction of hepatocyte-like cells from fbroblasts. Journal of cellular biochemistry 114, 256-265, doi: 10.1002/jcb.24380 (2013).
55. Cameron, K., Lucendo-Villarin, B., Szkolnicka, D. & Hay, D. C. Serum-Free Directed Diferentiation of Human Embryonic Stem Cells to Hepatocytes. Methods in molecular biology 1250, 105-111, doi: 10.1007/978-1-4939-2074-7-7 (2015).
56. Mallanna, S. K. & Duncan, S. A. Diferentiation of hepatocytes from pluripotent stem cells. Current protocols in stem cell biology 26, Unit 1G 4, doi: 10.1002/9780470151808.sc01g04s26 (2013).